|
gptkbp:instanceOf
|
gptkb:drug
biologic medication
|
|
gptkbp:administeredBy
|
solution for injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2002
|
|
gptkbp:ATCCode
|
L03AB11
|
|
gptkbp:brand
|
gptkb:Pegasys
|
|
gptkbp:CASNumber
|
198153-51-4
|
|
gptkbp:chemicalFormula
|
C860H1353N229O255S9
|
|
gptkbp:combines
|
ribavirin
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
|
|
gptkbp:drugClass
|
interferons
|
|
gptkbp:eliminationHalfLife
|
50-80 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
peginterferon alfa-2a
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
interferon alpha receptor agonist
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
gptkb:D_(Australia)
|
|
gptkbp:product
|
gptkb:pegylated_interferon_alpha-2a
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
neutropenia
thrombocytopenia
flu-like symptoms
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:UNII
|
6J9B8M8YKA
|
|
gptkbp:usedFor
|
gptkb:hepatitis_C
gptkb:hepatitis_B
|
|
gptkbp:bfsParent
|
gptkb:Ribavirin
gptkb:L03AB08
gptkb:Pegasys
gptkb:L03AB13
|
|
gptkbp:bfsLayer
|
7
|